FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.

The FDA's upcoming panel discussion on easing restrictions for peptides, a group of unapproved drugs, has sparked controversy due to the inclusion of experts who advocate for these unproven chemicals, a stance favored by Robert F. Kennedy Jr.'s followers. This meeting, set for next month, could influence public health decisions by potentially allowing wider use of these substances, despite their lack of regulatory approval. The implications are significant, as the FDA's decision could shape the future landscape of drug regulation and patient safety.